The role of genomic copy number variants (CNV) in the development of congenital heart defects (CHD) is not entirely known. Array CGH has clinical value in the identification of CNVs for CHD; however, accurate phenotyping of the CHD lesion and the presence of extra-cardiac features may affect its utility. Our aim was to determine the CNV rate in CHD cases (prenatal and postnatal) with normal karyotype, and to evaluate how the diagnostic yield of aCGH varies with the complexity of the cardiac defect and the presence of extra-cardiac abnormalities.
OBJECTIVE:
The role of genomic copy number variants (CNV) in the development of congenital heart defects (CHD) is not entirely known. Array CGH has clinical value in the identification of CNVs for CHD; however, accurate phenotyping of the CHD lesion and the presence of extra-cardiac features may affect its utility. Our aim was to determine the CNV rate in CHD cases (prenatal and postnatal) with normal karyotype, and to evaluate how the diagnostic yield of aCGH varies with the complexity of the cardiac defect and the presence of extra-cardiac abnormalities.
STUDY DESIGN: A retrospective cohort study was conducted between January 2010-October 2016 at a single institution; 185 patients diagnosed with at least one congenital heart defect [prenatal (n¼28); postnatal, 1 year of age (n¼157)] and who had undergone aCGH testing were included. CHDs were categorized as simple or complex, isolated or non-isolated (i.e., associated with other structural or functional abnormalities). Fisher's Exact test was used for CNV frequency comparison. RESULTS: The overall diagnostic yield of aCGH in cases with CHD was 20%; 22q11 microdeletion was observed in 11 (29%) cases, decreasing the rate to 14.5% when excluded. Eighty-nine percent of CNVs were pathogenic and 11% were variants of unknown significance (VUS). Sixty-eight percent of CNVs were copy number loss, 27% were gain, and 5% were combined (Table 1) . A high diagnostic yield of aCGH was observed in all CHD categories. The highest detection rate of CNVs was in the combined complex + non-isolated CHD group (28 %), but still at 18% in the combined simple + isolated CHD group ( Table 2 ). The diagnostic yield of aCGH in the prenatal cohort was 28 % (8/28) and 18.4% (29/157) postnatally. CONCLUSION: Array CGH detects clinically significant CNVs in patients with CHD, regardless of test timing, complexity of the lesion, and the presence of extra-cardiac abnormalities. The rate is highest for those with complex CHD that is non-isolated, although associated extra-cardiac findings appear to be the primary driver of risk. This information may be clinically valuable in the pretest counseling process.
Poster Session V ajog.org 
